Akash Tewari
Stock Analyst at Jefferies
(1.45)
# 3,276
Out of 4,835 analysts
61
Total ratings
31.11%
Success rate
-6.69%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $6.49 | +54.08% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $46.75 | +45.45% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $59.27 | +60.28% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $92.77 | +61.69% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $2.81 | +469.40% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $121.02 | +56.17% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $17.45 | +358.45% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $33.56 | +123.48% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $757.39 | +34.01% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $31.42 | +59.13% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $40.61 | +84.68% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $15.18 | +104.22% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $594.32 | +57.66% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $2.25 | +433.33% | 2 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $22.83 | +70.83% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $5.76 | +212.77% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $565.63 | -9.30% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.88 | +525.00% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $76.06 | +64.34% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $11.71 | -6.06% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $5.18 | -30.50% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.15 | +1,378.26% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $31.00 | +141.94% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $290.96 | -48.10% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $45.40 | -38.33% | 3 | Oct 7, 2021 |
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $6.49
Upside: +54.08%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $46.75
Upside: +45.45%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $59.27
Upside: +60.28%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $92.77
Upside: +61.69%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $2.81
Upside: +469.40%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $121.02
Upside: +56.17%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $17.45
Upside: +358.45%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $33.56
Upside: +123.48%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $757.39
Upside: +34.01%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $31.42
Upside: +59.13%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $40.61
Upside: +84.68%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $15.18
Upside: +104.22%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $594.32
Upside: +57.66%
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $2.25
Upside: +433.33%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $22.83
Upside: +70.83%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $5.76
Upside: +212.77%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $565.63
Upside: -9.30%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $2.88
Upside: +525.00%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $76.06
Upside: +64.34%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $11.71
Upside: -6.06%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $5.18
Upside: -30.50%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.15
Upside: +1,378.26%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $31.00
Upside: +141.94%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $290.96
Upside: -48.10%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $45.40
Upside: -38.33%